It showed that 84 percent of people who responded to atezolizumab
continued to respond regardless of their PD-L1 status when the results
were assessed with longer median follow-up of 11.7 months.
play
Roche says encouraged by cancer drug atezolizumab study(Reuters)
Roche, the world's biggest maker of cancer drugs, said a mid-stage trial of atezolizumab
in people with locally advanced or metastatic urothelial carcinoma
(mUC), showed median overall survival of 11.4 months in people with
higher levels of PD-L1 expression and 7.9 months in the overall study
population.
It showed that 84 percent of people
who responded to atezolizumab continued to respond regardless of their
PD-L1 status when the results were assessed with longer median follow-up
of 11.7 months.
The therapy was well tolerated and adverse events were consistent with those observed in previous updates, it said.
"It
is encouraging to see that the majority of people with advanced bladder
cancer who responded to atezolizumab maintained their response with
longer follow up," said Sandra Horning, Roche's chief medical officer and head of global product development.
Roche plans to submit the data soon to health authorities and the U.S. Food and Drug Administration
under breakthrough therapy designation designed to speed the
development and review of medicines that may demonstrate substantial
improvement over existing therapies for serious diseases.
No comments:
Post a Comment